World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
A personalized mRNA cancer vaccine developed by Moderna and Merck has cut the risk of melanoma recurrence or death by 42 percent when combined with immunotherapy in a landmark clinical trial. The results of the late-stage trial, presented at the European Society for Medical Oncology conference, establish skin cancer as a proving ground for customized genetic immunotherapy. Researchers describe the clinical findings as phenomenal and a triumph of science, marking a major milestone in the development of individualized treatments for oncology patients.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ A personalized mRNA cancer vaccine reduced the risk of melanoma recurrence or death by 42 percent when combined with immunotherapy in a landmark clinical trial.
- ✓ Moderna and Merck developed the mRNA cancer vaccine evaluated in the late-stage trial.
What changed
Moderna and Merck released complete late-stage clinical trial data at the ESMO presentation confirming a 42 percent risk reduction for melanoma recurrence or death.
Live updates
-
Melanoma Vaccine Cuts Recurrence and Death Risk
A personalized mRNA cancer vaccine developed by Moderna and Merck has cut the risk of melanoma recurrence or death by 42 percent when combined with immunotherapy in a landmark clinical trial. The results of the late-stage trial, presented at the European Society for Medical Oncology conference, establish skin cancer as a proving ground for customized genetic immunotherapy. Researchers describe the clinical findings as phenomenal and a triumph of science, marking a major milestone in the development of individualized treatments for oncology patients.
Why it matters
The trial data evaluated the combination of the mRNA vaccine with established immunotherapy treatments to combat late-stage melanoma. This therapeutic approach tailors the vaccine to the specific genetic mutations of an individual patient's tumor. The findings represent a key validation of mRNA technology outside of infectious disease applications.
What is confirmed
- A personalized mRNA cancer vaccine reduced the risk of melanoma recurrence or death by 42 percent when combined with immunotherapy in a landmark clinical trial.
- Moderna and Merck developed the mRNA cancer vaccine evaluated in the late-stage trial.
What to watch next
- Broader regulatory submissions and review timelines by health authorities.
- Initiation of late-stage trials for other cancer types using the personalized mRNA platform.
confidence 100%Sources used for this update (21)
- www.bbc.com — World | Latest News & Updates | BBC News
- apnews.com — World News: Top & Breaking World News Today | AP News
- www.nytimes.com — World News
- www.cbsnews.com — World news: Latest news, breaking news, today's news stories from...
- www.foxnews.com — World News Today Updates & Daily Headlines | Fox News
- www.nbcnews.com — World News: International Headlines, Breaking Reports and Video
- www.worldatlas.com — World Map / World Atlas / Atlas of the World Including Geography...
- abcnews.com — International News | Latest World News, Videos & Photos
- Ars Technica — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
- NBC News — Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
- WSJ — Moderna Investors Should Brace for More Whiplash
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community